Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Alliance Pharma deal an important step towards internationalisation, says City research house

The latest addition to the Alliance Pharma medicine chest represents an “important step to the internationalisation of the group”, according to a City research house. 
Alliance Pharma deal an important step towards internationalisation, says City research house

The latest addition to the Alliance Pharma (LON:APH) medicine chest represents an “important step to the internationalisation of the group”, according to the City research house Hardman & Co.

Alliance said last week it will pay US$11.5mln to acquire full ownership of obstetric drug Syntometrine from Swiss giant Novartis.

The speciality pharma group already owns the UK rights to the treatment, which is used in the final stages of labour.

However, Syntometrine sells in around a dozen other major territories, including Australia, South Africa, Malaysia and New Zealand.

Hardman is predicting Alliance’s overseas revenues will rise to around 30% of total sales in 2014, compared with just 18% last year.

Analysts point out the deal uses the blue-print that underpins company’s success – acquiring prescription drugs that require little or no marketing, but generate a solid revenue stream.

Outside the UK Syntometrine generates sales of US$3.2mln. 

Adjusting for inventories, Alliance has paid 3.5 times turnover and 5.5 times earnings for the product, specialist small-cap broker FinnCap said.   

“We believe is a fair price and in line with the multiples we have seen historically for such acquisitions.” 

At 11.30am, the shares were little changed at 37.9 pence, valuing Alliance Pharma at £94mln. In the past year the stock has increased in value by a third.

View full APH profile View Profile

Alliance Pharma plc Timeline

Newswire
July 31 2017

Related Articles

cancer cells from taken by an electron microscope
March 13 2018
Sareum has partnered with Sierra Oncology to advance the company's Checkpoint kinase 1 inhibitor
scientist looking through a microscope
October 31 2017
As of March, ReNeuron had £53mln in cash equivalents but its market value is not too much above that....
newspaper with word cancer magnified
January 15 2018
"In our view, the potential for SCIB1 [Scancell's skin cancer treatment], as already demonstrated by the survival data, is remarkable," said one broker recently

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use